Genentech, Roche sink potential $600M into advanced prostate cancer assetR&D, TherapeuticsGenentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer. Read more August 18, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2021/07/Genentechs-Combo-Therapy-for-Rare-Blood-Cancers-Scores-Breakthrough-Designation-BioSpace-7-21-21.jpeg 350 625 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-08-18 10:57:152022-08-18 10:57:15Genentech, Roche sink potential $600M into advanced prostate cancer asset
